Related Experiment Video

Updated: Jun 23, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Accepting risk in the acceleration of drug development for rare cancers

David Ashley1, David Thomas2, Lia Gore3

  • 1School of Medicine, Deakin University, Geelong, VIC, Australia; Andrew Love Cancer Centre, Barwon Health, Geelong, VIC, Australia.

The Lancet. Oncology
|April 8, 2015
PubMed

Insights

Rare cancers pose challenges for clinical trials due to small patient numbers. Increased risk-sharing is crucial for developing targeted therapies and advancing rare cancer care.

Area of Science:

  • Oncology
  • Rare Cancers
  • Clinical Trials

Background:

  • Rare cancers represent a significant cancer burden.
  • Small patient cohorts per subtype necessitate multicenter collaborations for clinical trials.
  • Advances in rare cancer biology are driving the development of targeted agents.

Purpose of the Study:

  • To address the challenges in rare cancer drug development.
  • To propose solutions for the increasing complexity and costs of clinical trials.
  • To advocate for enhanced risk-sharing models in rare cancer research.

Main Methods:

  • Review of current challenges in rare cancer clinical trials.
  • Analysis of the impact of biological insights on targeted agent development.
  • Proposal for a revised risk-sharing framework for drug development.

Main Results:

  • Current drug development strategies are hindered by trial complexities and costs.
  • New biological insights offer revolutionary potential for rare cancer treatment.
  • Existing risk-sharing models are insufficient for the pace of scientific advancement.

Conclusions:

  • Greater risk-sharing is imperative for rare cancer drug development.
  • Implementing new methods requires confidence and adaptation to scientific progress.
  • Addressing these issues is vital for the future of oncology care for rare cancer patients.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Automating Tumor Implantation in Zebrafish Larvae for Cancer Research and Medicine06:14

Automating Tumor Implantation in Zebrafish Larvae for Cancer Research and Medicine

Published on: September 19, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...